Sentence examples for circulation lifetime from inspiring English sources

Protein and peptide therapeutics with good in vitro activities often fail due to poor bioavailability, circulation lifetime, and immunogenicity.

An extended circulation lifetime allows them to take advantage of the enhanced permeability and retention effect (EPR), resulting in increased delivery to target sites.

As a result, PFV can be designed to display a long circulation lifetime after i.v. administration, high accumulation at disease sites and full bioavailability of an encapsulated compound.

These results suggested that PVP is the most suitable polymeric modifier for prolonging the circulation lifetime of a drug and localizing the conjugated drug in blood.

However, effective and safe systemic delivery of siRNA into the brain remains challenging because of biological barriers such as enzymatic degradation, short circulation lifetime, the blood brain barrier (BBB), insufficient tissue penetration, cell endocytosis, and cytosolic transport.

Specifically, we elaborate on the components (choice of lipids, molar proportions, etc)., methods (preparation of liposomes, drug loading methods, etc)., critical design features (size, surface charge, etc)., and key biological endpoints (circulation lifetime, bioavailability, efficacy measurements) important to the development of a formulation of vincristine with enhanced therapeutic properties.

The addition of poly (ethylene glycol -lipids (PEglycol -lipidsongs circulation lifetimes of liPEGylationut inhibits cellular uprolongsd endosomal escirculationDNA complifetimes

In this study we wanted to determine whether highly charged cationic liposomes with surface-associated PEG could be designed to exhibit extended circulation lifetimes, while retaining tumor vascular targeting properties in an HT29 colorectal cancer xenograft model.

We show for the first time that it is achievable to design highly charged, highly pegylated (20 mol% DSPE-PEG2000) cationic liposomes which exhibit both extended circulation lifetimes and tumor vascular targeting properties.

Incorporating 15 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE -PEG 2000 into PS liposomes resulteDSPE -PEGulation lifetimes comparable to that obtained with neutral liposomes containing 5 mol% DSPE-PEG 2000.

Polymer layers have also been shown to improve the in vivo circulation lifetimes of proteins, which is a pharmacological barrier to clinical relevance for protein therapeutics.